Leniolisib

(Joenja®)

Leniolisib

Drug updated on 4/16/2024

Dosage FormTablet (oral; 70 mg)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated, with no liability accepted for reliance on it. Learn more.

  • Leniolisib (Joenja) is indicated for the treatment of activated phosphoinositide 3-kinase delta syndrome in adult and pediatric patients aged 12 years and older. The medication presents a favorable safety profile, with fewer study treatment-related adverse events reported compared to placebo.
  • A study from a randomized controlled trial was reviewed to gather information about Joenja's safety and effectiveness.
  • In terms of effectiveness, leniolisib significantly outperformed the placebo in all reported outcomes including reduction in lymph node size, increase in the percentage of naive B cells, and decrease in spleen volume. These results underscore its proficiency in addressing key pathological features associated with APDS such as lymphadenopathy, immune dysregulation, and deficiency.
  • The comparison was made only against a placebo; no direct comparison was made between leniolisib (Joenja) and other medications used for treating APDS. However, it demonstrated significant improvement over the inactive treatment option.
  • The population targeted by the study were patients with ADPS who are at least 12 years old, which provides valuable insights into Joenja's applicability across both adult and pediatric age groups suffering from ADPS.
  • No subgroup analyses based on age or other demographic or clinical characteristics were mentioned, limiting understanding of differential impacts, if any, among these subgroups while using leniolisib (Joenja).

Product Monograph / Prescribing Information

Document TitleYearSource
Joenja (leniolisib) Prescribing Information. 2023Pharming Group N.V., Leiden, The Netherlands

Randomized Controlled Trials

Clinical Practice Guidelines